Abstract:Background: Proline-rich transmembrane protein 2 (PRRT2) plays an important role in the central nervous system and mutations in the gene are implicated in a variety of neurological disorders. This study aimed to summarize the clinical characteristics and gene expression analysis of neurological diseases related to the PRRT2 gene and explore the clinical characteristics, therapeutic effects, and possible pathogenic mechanisms of related diseases. Methods: We enrolled 10 children with PRRT2 mutation-related neurological diseases who visited the Children's Hospital affiliated with the Shanghai Jiaotong University School of Medicine/Shanghai Children's Hospital between May 2017 and February 2022. Video electroencephalography (VEEG), cranial imaging, treatment regimens, gene results, and gene expression were analyzed. Genetic testing involved targeted sequencing or whole-exome genome sequencing (WES). We further analyzed the expression and mutation conservation of PRRT2 and synaptosome-associated protein 25 (SNAP25) in blood samples using quantitative polymerase chain reaction (qPCR) and predicted the protein structure. Summary analysis of the reported gene maps and domains was also performed. Results: Ten children with PRRT2 gene mutations were analyzed, and 4 mutations were identified, consisting of 2 new (c.518A > C, p.Glu173 Ala; c.879 + 112G > A, p.?) and two known (c. 649 dup, p. Arg217Profs * 8; c. 649 del, p. Arg217Glufs * 12) mutations. Among these mutations, one was de novo (P6), and three could not be determined because one parent refused genetic testing. The clinical phenotypes were paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), epilepsy, infantile spasms, and intellectual disability. The qPCR results showed that PRRT2 gene expression levels were significantly lower in children and parent carriers than the control group. The SNAP25 gene expression level of affected children was significantly lower ( P ≤ 0.001) than that of the control group. The mutation sites reported in this study are highly conserved in different species. Among the various drugs used, oxcarbazepine and sodium valproate were the most effective. All 10 children had a good disease prognosis, and 8 were completely controlled with no recurrence, whereas 2 had less severe and fewer seizures. Conclusion: Mutation of PRRT2 led to a significant decrease in its protein expression level and that of SNAP25, suggesting that the mutant protein may lead to the loss of its function and that of related proteins. This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.

PRRT2 Frameshift Mutation Reduces Its Mrna Stability Resulting Loss of Function in Paroxysmal Kinesigenic Dyskinesia

Phenotypic Overlap among Paroxysmal Dyskinesia Subtypes: Lesson from a Family with PRRT2 Gene Mutation.

Novel mutation of the PRRT2 gene in two cases of paroxysmal kinesigenic dyskinesia: Two case reports

[Clinical Features and PRRT2 Gene Mutation in Paroxysmal Kinesigenic Dyskinesia].

PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures.

PRRT2 Truncated Mutations Lead to Nonsense-Mediated Mrna Decay in Paroxysmal Kinesigenic Dyskinesia

PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic transmission in cerebellum

Altered Intrinsic Brain Activity in Patients with Paroxysmal Kinesigenic Dyskinesia by PRRT2 Mutation

Exome Sequencing Identifies Truncating Mutations in PRRT2 That Cause Paroxysmal Kinesigenic Dyskinesia

Phenotypes and PRRT2 mutations in Chinese families with benign familial infantile epilepsy and infantile convulsions with paroxysmal choreoathetosis

PRRT2 C.649dupc Mutation Derived from De Novo in Paroxysmal Kinesigenic Dyskinesia

Genetic and phenotypic analyses of PRRT2 positive and negative paroxysmal kinesigenic dyskinesia

Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosis.

Mutation Analysis of MR-1, SLC2A1, and CLCN1 in 28 PRRT2-negative Paroxysmal Kinesigenic Dyskinesia Patients.

A PRRT2 Variant in a Chinese Family with Paroxysmal Kinesigenic Dyskinesia and Benign Familial Infantile Seizures Results in Loss of Interaction with STX1B

Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias.

Clinical Manifestations in Paroxysmal Kinesigenic Dyskinesia Patients with Proline-Rich Transmembrane Protein 2 Gene Mutation

Novel PRRT2 Mutations in Paroxysmal Dyskinesia Patients with Variant Inheritance and Phenotypes

Prrt2 Mutation Screening in Patients with Paroxysmal Kinesigenic Dyskinesia from Southwest China

Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases

Clinical and Genetic Analyses of 150 Patients with Paroxysmal Kinesigenic Dyskinesia.